Loading
Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer.
Ken Kato was principal investigator of ATTRACTION-3, the first trial to show a checkpoint inhibitor (nivolumab) improves survival in previously treated oesophageal squamous cell carcinoma, and co-led KEYNOTE-590, which established pembrolizumab plus chemotherapy first line. He leads JCOG oesophageal trials and heads oesophageal medical oncology at Japan's National Cancer Center.
Shares Oesophageal cancer, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags esophageal, immunotherapy.
Shares Oesophageal cancer, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags esophageal, immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.